Surgery Partners (SGRY) saw its stock plummet 5.23% in pre-market trading on Monday following the release of its first-quarter 2025 financial results, which fell short of analysts' expectations. The ambulatory surgery center operator reported disappointing earnings and a slight revenue miss, causing concern among investors.
The company announced adjusted earnings per share of $0.04 for Q1, a significant decline from $0.10 in the same period last year and below the FactSet consensus estimate of $0.05. Revenue for the quarter came in at $776 million, narrowly missing the analysts' projection of $777.07 million, despite showing growth from $717.4 million in the previous year.
Despite the earnings setback, Surgery Partners reaffirmed its full-year 2025 revenue guidance of $3.30 billion to $3.45 billion, in line with analysts' expectations of $3.39 billion. However, this reassurance did little to alleviate investor concerns in early trading. The company's ability to meet its annual targets will likely be closely scrutinized in the coming quarters, given the softer-than-expected start to the year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。